New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
07:06 EDTGEVASynageva issued U.S. patent for treatment of LAL deficiency
Synageva BioPharma announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,663,631 covering methods of treating lysosomal acid lipase deficiency. This patent provides protection until 2031, not including any patent term extension. The patent complements Synageva’s existing and planned global patent portfolio covering its LAL Deficiency program, which includes intellectual property directed to composition of matter, methods of use, and manufacturing.
News For GEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for GEVA

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use